MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 1, 2011, Pages 127-133

  Tunstall, Radhika R ^a   Shukla, Praveen ^a   Grazul Bilska, Anna ^a   Sun, Chengwen ^a   O'Rourke, Stephen T ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYL 2 PROPIONAMIDOTETRALIN; 5 METHOXYCARBONYLAMINO N ACETYLTRYPTAMINE; 8 BROMO CYCLIC GMP; ALPHA ACTIN; BRIMONIDINE; CYCLIC GMP; LUZINDOLE; MELATONIN; MELATONIN 2 RECEPTOR; N ACETYLTRYPTAMINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG; NITRIC OXIDE DONOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING; ANIMAL; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SWINE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; CORONARY VESSELS; MELATONIN; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE DONORS; RECEPTOR, MELATONIN, MT2; SWINE; VASODILATION;

EID: 78650800876     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.174482     Document Type: Article

References (45)

1. 2 receptors. Naunyn Schmiedebergs Arch Pharmacol 367:553-561.
2. Bockman CS, Gonzalez-Cabrera I, and Abel PW (1996) Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. J Pharmacol Exp Ther 278:1235-1243.
3. Boutin JA, Audinot V, Ferry G, and Delagrange P (2005) Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci 26:412-419.
4. Browning C, Beresford I, Fraser N, and Giles H (2000) Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors. Br J Pharmacol 129:877-886.
5. Brugger P, Marktl W, and Herold M (1995) Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 345:1408.
6. 2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. Endocrinology 142:4264-4271.
7. Capsoni S, Stankov BM, and Fraschini F (1995) Reduction of regional cerebral blood flow by melatonin in young rats. Neuroreport 6:1346-1348.
8. Domínguez-Rodríguez A, Abreu-González P, García MJ, Sanchez J, Marrero F, and de Armas-Trujillo D (2002) Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 33:248-252.
9. Doolen S, Krause DN, Dubocovich ML, and Duckles SP (1998) Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol 345:67-69.
10. Dubocovich ML (1988) Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther 246:902-910.
11. 2 melatonin receptors in mammals. Endocrine 27:101-110.
12. Dubocovich ML, Masana MI, Iacob S, and Sauri DM (1997) Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol 355:365-375.
13. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, and Masana MI (2003) Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 8:d1093-d1108.
14. 2 is present in the human cardiovascular system. J Pineal Res 35:40-44.
15. Evans BK, Mason R, and Wilson VG (1992) Evidence for direct vasoconstrictor activity of melatonin in "pressurized" segments of isolated caudal artery from juvenile rats. Naunyn Schmiedebergs Arch Pharmacol 346:362-365.
16. Finocchiaro LM, Nahmod VE, and Launay JM (1991) Melatonin biosynthesis and metabolism in peripheral blood mononuclear leucocytes. Biochem J 280:727-731.
17. Flavahan NA, Shimokawa H, and Vanhoutte PM (1989) Pertussis toxin inhibits endothelium-dependent relaxations to certain agonists in porcine coronary arteries. J Physiol 408:549-560.
18. Geary GG, Krause DN, and Duckles SP (1997) Melatonin directly constricts rat cerebral arteries through modulation of potassium channels. Am J Physiol 273:H1530-H1536.
19. Girotti L, Lago M, Ianovsky O, Elizari MV, Dini A, Lloret SP, Albornoz LE, and Cardinali DP (2003) Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure. Endocrine 22:245-248.
20. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, and Gruetter CA (1981) Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 218:739-749.
21. Jonas M, Garfinkel D, Zisapel N, Laudon M, and Grossman E (2003) Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 12:19-24.
22. Kowaluk EA, Seth P, and Fung HL (1992) Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle. J Pharmacol Exp Ther 262:916-922.
23. Krause ND, Geary GG, Doolen S and Duckles PS (2000) Melatonin and cardiovascular function, in Melatonin after Four Decades: An Assessment of Its Potential (Olcese J ed) pp 299-310, Kluwer Academic/Plenum Publishers, New York.
24. Kvetnoy IM (1999) Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem J 31:1-12.
25. Mahle CD, Goggins GD, Agarwal P, Ryan E, and Watson AJ (1997) Melatonin modulates vascular smooth muscle tone. J Biol Rhythms 12:690-696.
26. Masana MI, Doolen S, Ersahin C, Al-Ghoul WM, Duckles SP, Dubocovich ML, and Krause DN (2002) MT(2) melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther 302:1295-1302.
27. Monroe KK and Watts SW (1998) The vascular reactivity of melatonin. Gen Pharmacol 30:31-35.
28. Murad F (1986) Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 78:1-5.
29. Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, Fauchere JL, Delagrange P, Canet E, and Boutin JA (2000) Identification of the melatoninbinding site MT3 as the quinone reductase 2. J Biol Chem 275:31311-31317.
30. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, and Cardinali DP (2008) Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 85:335-353.
31. Petit L, Lacroix I, de Coppet P, Strosberg AD, and Jockers R (1999) Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3'-5'-monophosphate pathway. Biochem Pharmacol 58:633-639.
32. Pintor J, Martin L, Pelaez T, Hoyle CH, and Peral A (2001) Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. Eur J Pharmacol 416:251-254.
33. 2 melatonin receptor expression in extrapineal tissues of the rat during physiological aging. J Pineal Res 46:29-35.
34. Sallinen P, Mänttäri S, Leskinen H, Ilves M, Vakkuri O, Ruskoaho H, and Saarela S (2007) The effect of myocardial infarction on the synthesis, concentration and receptor expression of endogenous melatonin. J Pineal Res 42:254-260.
35. Satake N, Oe H, and Shibata S (1991) Vasorelaxing action of melatonin in rat isolated aorta; possible endothelium dependent relaxation. Gen Pharmacol 22:1127-1133.
36. Savaskan E, Olivieri G, Brydon L, Jockers R, Kräuchi K, Wirz-Justice A, and Müller-Spahn F (2001) Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer's disease. Neurosci Lett 308:9-12.
37. Silva CL, Tamura EK, Macedo SM, Cecon E, Bueno-Alves L, Farsky SH, Ferreira ZS, and Markus RP (2007) Melatonin inhibits nitric oxide production by microvascular endothelial cells in vivo and in vitro. Br J Pharmacol 151:195-205.
38. Stankov B and Fraschini F (1993) High affinity melatonin binding sites in the vertebrate brain. Neuro Endocrinol Lett 15:149-164.
39. Stankov B, Capsoni S, Lucini V, Fauteck J, Gatti S, Gridelli B, Biella G, Cozzi B, and Fraschini F (1993) Autoradiographic localization of putative melatonin receptors in the brains of two Old World primates: Cercopithecus aethiops and Papio ursinus. Neuroscience 52:459-468.
40. Stumpf I, Mühlbauer E, and Peschke E (2008) Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells. J Pineal Res 45:318-327.
41. Ting KN, Dunn WR, Davies DJ, Sugden D, Delagrange P, Guardiola- Lemaître B, Scalbert E, and Wilson VG (1997) Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats. Br J Pharmacol 122:1299-1306.
42. Viswanathan M, Laitinen JT, and Saavedra JM (1990) Expression of melatonin receptors in arteries involved in thermoregulation. Proc Natl Acad Sci USA 87:6200-6203.
43. Viswanathan M, Scalbert E, Delagrange P, Guardiola-Lemaître B, and Saavedra JM (1997) Melatonin receptors mediate contraction of a rat cerebral artery. Neuroreport 8:3847-3849.
44. Weekley LB (1991) Melatonin-induced relaxation of rat aorta: interaction with adrenergic agonists. J Pineal Res 11:28-34.
45. Yang Q, Scalbert E, Delagrange P, Vanhoutte PM, and O'Rourke ST (2001) Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. Am J Physiol 280:H76-H82.